SeaStar Medical is trading 7.77% lower at $3.43, with no new company announcement identified to explain the decline.
- On October 7, shares gained 16.61% to $3.72 after the FDA granted Breakthrough Device Designation to its SCD therapy for adult sepsis-related hyperinflammation; that announcement does not explain the October 8 decline.
- The broader market is softer, but reported losses are modest, and healthcare is higher, so neither clearly accounts for the move.